Original Source(s)
Related Content
FDA approves FET-PET agent for glioma
The radioactive diagnostic drug is indicated in patients aged 1 month or older and is used in conjunction with other diagnostic evaluations.
September 14, 2026
-
2 min
FDA approves combo for ESR1-mutated breast cancer
In an exploratory subgroup analysis of patients with ESR1-mutated tumors, median progression-free survival was 11.1 months with the combination and 5.5 months with imlunestrant alone.
September 21, 2026
-
2 min
Hot drink habits and esophageal cancer
Researchers assessed preferred hot drink temperature and consumption frequency across 2 large UK cohorts.
September 16, 2026
-
4 min